Avalo Therapeutics, Inc. (AVTX)

Market Cap	93.17M
Revenue (ttm)	441,000
Net Income (ttm)	-35.13M
Shares Out	10.67M
EPS (ttm)	-20.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,922
Open	8.40
Previous Close	8.36
Day's Range	7.95 - 9.04
52-Week Range	4.60 - 34.46
Beta	0.86
Analysts	Strong Buy
Price Target	34.33 (+293.24%)
Earnings Date	May 12, 2025

About AVTX

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company’s drug candidates include AVTX-009, an Anti-IL-1β monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory dis...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 15, 2015
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: AVTX
• Website: https://www.avalotx.com

Financial Performance

In 2024, Avalo Therapeutics's revenue was $441,000, a decrease of -77.08% compared to the previous year's $1.92 million. Losses were -$35.13 million, 11.4% more than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for AVTX stock is "Strong Buy." The 12-month stock price forecast is $34.33, which is an increase of 293.24% from the latest price.

Price Target

$34.33

(293.24% upside)

Analyst Consensus: Strong Buy